221 related articles for article (PubMed ID: 31305009)
1. Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
Watanabe A; Inukai T; Kagami K; Abe M; Takagi M; Fukushima T; Fukushima H; Nanmoku T; Terui K; Ito T; Toki T; Ito E; Fujimura J; Goto H; Endo M; Look T; Kamps M; Minegishi M; Takita J; Inaba T; Takahashi H; Ohara A; Harama D; Shinohara T; Somazu S; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2019 Sep; 8(11):5274-5288. PubMed ID: 31305009
[TBL] [Abstract][Full Text] [Related]
2. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
den Boer ML; Pieters R; Kazemier KM; Rottier MM; Zwaan CM; Kaspers GJ; Janka-Schaub G; Henze G; Creutzig U; Scheper RJ; Veerman AJ
Blood; 1998 Mar; 91(6):2092-8. PubMed ID: 9490695
[TBL] [Abstract][Full Text] [Related]
3. Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report.
Wafa A; As'sad M; Liehr T; Aljapawe A; Al Achkar W
J Med Case Rep; 2017 Apr; 11(1):94. PubMed ID: 28385156
[TBL] [Abstract][Full Text] [Related]
4. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
5. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.
Ramakers-van Woerden NL; Beverloo HB; Veerman AJ; Camitta BM; Loonen AH; van Wering ER; Slater RM; Harbott J; den Boer ML; Ludwig WD; Haas OA; Janka-Schaub GE; Pieters R
Leukemia; 2004 Mar; 18(3):521-9. PubMed ID: 14712291
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Felice MS; Gallego MS; Alonso CN; Alfaro EM; Guitter MR; Bernasconi AR; Rubio PL; Zubizarreta PA; Rossi JG
Leuk Lymphoma; 2011 Jul; 52(7):1215-21. PubMed ID: 21534874
[TBL] [Abstract][Full Text] [Related]
7. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
[TBL] [Abstract][Full Text] [Related]
8. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia.
Pieters R; Hongo T; Loonen AH; Huismans DR; Broxterman HJ; Hählen K; Veerman AJ
Br J Cancer; 1992 May; 65(5):691-7. PubMed ID: 1350207
[TBL] [Abstract][Full Text] [Related]
9. [Multidrug resistant gene MDR1 contributes to development of imatinib-resistance in Ph (+) acute lymphoblastic leukemia cell line SUP-BS15RI].
Lin J; Xing HY; Gong YP; Yang X; Guo Y; Shan QQ; Zhou RQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 43(5):657-60, 665. PubMed ID: 23230732
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples.
Estes DA; Lovato DM; Khawaja HM; Winter SS; Larson RS
Br J Haematol; 2007 Oct; 139(1):20-30. PubMed ID: 17854304
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias.
Paulsson K; Jonson T; Ora I; Olofsson T; Panagopoulos I; Johansson B
Br J Haematol; 2007 Jul; 138(2):196-201. PubMed ID: 17593026
[TBL] [Abstract][Full Text] [Related]
12. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
[TBL] [Abstract][Full Text] [Related]
13. Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.
Reichle A; Diddens H; Altmayr F; Rastetter J; Andreesen R
Cancer Chemother Pharmacol; 1994; 34(4):307-16. PubMed ID: 7913420
[TBL] [Abstract][Full Text] [Related]
14. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.
Yilmaz M; Kantarjian HM; Toruner G; Yin CC; Kanagal-Shamanna R; Cortes JE; Issa G; Short NJ; Khoury JD; Garcia-Manero G; Ravandi F; Kadia T; Konopleva M; Wierda WG; Jain N; Estrov Z; Sasaki K; Pierce S; O'Brien SM; Jabbour EJ
Leuk Lymphoma; 2021 Jan; 62(1):224-228. PubMed ID: 32955970
[TBL] [Abstract][Full Text] [Related]
15. [Effect of Huaier Aqueous Extract Combined with Routine Chemo-therapeutic Drugs on Human Acute Lymphoblastic Leukemia Cells Nalm-6 and Sup-B15].
Qu P; Zhou F; Tan LF; Wang ZJ; Wang ML; Jin RM; Han J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1451-1458. PubMed ID: 33067936
[TBL] [Abstract][Full Text] [Related]
16. TCF3 gene rearrangements in pediatric B-cell acute lymphoblastic leukemia-A single center experience.
Zerkalenkova E; Menchits Y; Borkovskaia A; Sokolova S; Soldatkina O; Mikhailova E; Popov A; Komkov A; Rumiantseva Y; Karachunskii A; Olshanskaya Y
Int J Lab Hematol; 2023 Aug; 45(4):533-540. PubMed ID: 37058324
[TBL] [Abstract][Full Text] [Related]
17. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
Ribera J; Granada I; Morgades M; González T; Ciudad J; Such E; Calasanz MJ; Mercadal S; Coll R; González-Campos J; Tormo M; García-Cadenas I; Gil C; Cervera M; Barba P; Costa D; Ayala R; Bermúdez A; Orfao A; Ribera JM;
Br J Haematol; 2022 Feb; 196(3):670-675. PubMed ID: 34549416
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
Eldfors S; Kuusanmäki H; Kontro M; Majumder MM; Parsons A; Edgren H; Pemovska T; Kallioniemi O; Wennerberg K; Gökbuget N; Burmeister T; Porkka K; Heckman CA
Leukemia; 2017 Jan; 31(1):51-57. PubMed ID: 27461063
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression.
Baudis M; Prima V; Tung YH; Hunger SP
Pediatr Blood Cancer; 2006 Nov; 47(6):757-64. PubMed ID: 16206189
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of acute lymphocytic leukemia in adult].
Takahashi I; Inagaki N; Nakada H; Nishimura M; Hayashi N; Sekito N; Nonaka K; Takeuchi M; Osada K; Matuzaki T
Rinsho Ketsueki; 1989 Aug; 30(8):1167-70. PubMed ID: 2601026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
